The Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy/n
The Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy
GlobalData analysis finds that the prostate cancer therapeutics market in Japan is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.
Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. The introduction of new therapies for metastatic prostate cancer is expected to expand the market further.In 2009, the Japan accounted for approximately 5% of the global prostate cancer therapeutics market.
In 2009, Taxotere was the leading drug for hormone refractory prostate cancer with approximate sales worth $14m and a market share of 10.2% of the prostate cancer therapeutics market in Japan. Casodex and Zoladex were the most used therapy for hormone dependent prostate cancer patients and accounted for 80% of the total prostate cancer therapeutics market in Japan. The impact of generic competition for Casodex in 2008 and Taxotere in 2011 is expected to partially offset the growth in revenue due to new products launched in the forecast period 2009 to 2020.
The Current Competition in the Japanese Prostate Cancer Therapeutics Market is Weak as None of the Drugs Completely Addressed the Unmet Needs
The current competition in the Japanese prostate cancer therapeutics market is weak since none of the drugs are effective enough to address the high unmet needs existing in the market.
Taxotere is the only key drug for hormone-refractory prostate cancer. Other drugs such as Provenge and Jevtana are yet to be launched in the country. Mitoxantrone and estramustine which are also used in chemotherapy have lower efficacy. There are eight key drugs for hormone-dependent prostate cancer. These drugs do not completely address the unmet needs existing in the prostate cancer market. Hormone therapies dominate the prostate cancer therapeutics market, with relatively fewer options for the hormone-refractory prostate cancer therapeutics market. The current therapies cannot deliver the desired overall survival of 36 to 40 months and a progression free survival of 24 months.
The currently marketed drugs have failed to establish better efficacy and safety profiles than current clinicians’ targets. The key primary endpoint that clinicians target for efficacy in drugs tested for metastatic prostate cancer is the 24 month progression free survival and the 36 to 40 month overall survival. The best overall survival offered is 25.8 months by Provenge and 36 months by leuprolide acetate.
Safety is another major concern among the majority of the treatment regimens approved for metastatic prostate cancer. Adverse events such as anemia, neutropenia, thrombocytopenia, sensory neuropathy, hot flashes, body pain (back, pelvis and stomach), constipation, nausea, diarrhea, infection, swollen ankles, blood in the urine, weakness, dizziness and anemia are associated with leading prostate cancer therapies.
Therefore, clinicians are targeting late-stage molecules that can display better safety profile than Taxotere, bicalutamide, leuprolide and other prostate cancer regimens.
The Prostate Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development
The prostate cancer pipeline is strong. Currently, approximately 300 molecules are under development in about 400 research and development projects, including preclinical trials. Out of the 400 clinical trials that are currently being conducted for prostate cancer, Phase II clinical trials accounted for 57% while Phase I accounted for 18% followed by Phase III clinical trials. Phase III clinical trials accounted for 12% of the total research and development activities. More than 70% of the total clinical trials involved first-in-class compounds. Approximately 48% of the Phase III clinical trials are being conducted on first-in-class molecules.
For further details, please click or add the below link to your browser:
Even if a single molecule determines better efficacy and safety profile than the best available treatment regimen in the prostate cancer market, that drug would eventually become a blockbuster and will have the potential to tap the more than $1.1 billion in unmet need that currently exists in the global prostate cancer therapeutics market. This molecule is likely to capture a substantial share of the $52m unmet need in prostate cancer therapeutics market in Japan.
Currently, there are 300 molecules undergoing research and development for various stages of prostate cancer. The clinical trial results of Phase III molecules are highly unpredictable. The failures of clinical trial products such as Sutent (sunitinib), bevacizumab, satraplatin and atrasentan to demonstrate efficacy suggests the unpredictable nature of the clinical trials on leading compounds. In addition, Sanofi-aventis is working to gain approval in the European Union (EU). Jevtana is also expected to launch in Japan in the forecast period.
The prostate cancer pipeline also contains vaccines that are being tested for stage III prostate cancer. DCVax is in late-stage clinical development. Based on the successful launch of Provenge, which is a similar vaccine, the market scenario for these vaccines looks positive.
Some of the new mechanisms of action that are currently being tested for prostate cancer include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, tyrosine kinase inhibitors, DNA synthesis inhibitors, gonadotropin-releasing hormone (GnRH) receptor antagonists and so on.
For further details, please click or add the below link to your browser:
High Unmet Needs Exist in the Prostate Cancer Therapeutics Market in terms of Efficacy and Safety
In 2009, the unmet need in the prostate cancer therapeutics market was quantified and estimated at more than $52m in Japan. GlobalData analysis suggests that approximately 38% of the prostate cancer therapeutics market in Japan is underserved. This represents an unmet of more than 49% in hormone refractory prostate cancer therapeutics market and about 32.5% unmet need in hormone dependent prostate cancer therapeutics market. The value that can be captured by drugs, which are able to fulfill the unmet needs in the prostate cancer therapeutics market in Japan, is low.
However, globally the unmet need presents an opportunity of race for blockbusters in the prostate cancer therapeutics market.
The prostate cancer market has relatively high unmet needs in terms of efficacy and safety, with efficacy being the major concern. Higher unmet needs imply that the market is underserved by the current treatment options and therefore new entrants that can show a better efficacy profile than the best available treatment option will eventually capture market share in terms of both value and volume from the currently available therapies. In addition, there is an unmet need for drugs which can treat prostate cancer patients in earlier stages of development.
There is a scope for new entrants that possess the capability to tap the underserved segments. The currently available treatment options could not meet the clinicians’ target endpoints for 36-40 month survival rates. This was due to the limited efficacy and safety profiles of the currently marketed products. The current treatment options aim to slow the progression of the disease through hormone therapies and manage symptoms through hormone-refractory prostate cancer market. The market faces unmet need for effective chemotherapy for late-stage hormone-refractory prostate cancer. Recently approved products such as Provenge will help in addressing this unmet need to some extent in the coming years.
Additionally, the market also faces unmet need for second line chemotherapy options once Taxotere (the current chemotherapy for hormone-refractory prostate cancer) fails.
GlobalData, the industry analysis specialist, has released its new report, “Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the Japanese prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Japanese prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Japanese prostate cancer therapeutics market, highlighting the opportunity for future players.
Visit our report store: http://www.globaldata.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782